JP2017504570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504570A5 JP2017504570A5 JP2016534640A JP2016534640A JP2017504570A5 JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5 JP 2016534640 A JP2016534640 A JP 2016534640A JP 2016534640 A JP2016534640 A JP 2016534640A JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tauopathy
- composition according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909965P | 2013-11-27 | 2013-11-27 | |
| US61/909,965 | 2013-11-27 | ||
| PCT/US2014/067360 WO2015081085A2 (en) | 2013-11-27 | 2014-11-25 | Methods of treating a tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504570A JP2017504570A (ja) | 2017-02-09 |
| JP2017504570A5 true JP2017504570A5 (2) | 2017-09-28 |
| JP6629201B2 JP6629201B2 (ja) | 2020-01-15 |
Family
ID=52232410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534640A Expired - Fee Related JP6629201B2 (ja) | 2013-11-27 | 2014-11-25 | タウオパチーの処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160289309A1 (2) |
| EP (1) | EP3074420A2 (2) |
| JP (1) | JP6629201B2 (2) |
| CN (2) | CN105899230B (2) |
| BR (1) | BR112016010454A2 (2) |
| CA (1) | CA2931396C (2) |
| EA (1) | EA038994B1 (2) |
| MX (2) | MX384909B (2) |
| WO (1) | WO2015081085A2 (2) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| US20190010504A1 (en) * | 2015-12-11 | 2019-01-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| MX2019006330A (es) | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
| UA128383C2 (uk) | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| US20190135905A1 (en) * | 2017-06-16 | 2019-05-09 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
| WO2018231254A1 (en) * | 2017-06-16 | 2018-12-20 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| CN115607684A (zh) * | 2021-07-15 | 2023-01-17 | 华中科技大学 | 一种内耳药物纳米载体及其应用 |
| EP4426336A1 (en) * | 2021-11-03 | 2024-09-11 | Eisai R&D Management Co., Ltd. | Anti-tau antibody compositions, dosage forms, and methods |
| WO2025196217A1 (en) * | 2024-03-21 | 2025-09-25 | UCB Biopharma SRL | Treatment of tauopathies with tau-binding antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| WO1996019487A1 (en) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Organobismuth derivatives and process for producing the same |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| ES2166097T5 (es) | 1996-08-27 | 2007-03-16 | Novartis Vaccines And Diagnostics, Inc. | Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| KR20010015856A (ko) | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| AU2010286501B2 (en) * | 2009-08-28 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Antibodies that bind Tau oligomers |
| DK2496594T3 (en) * | 2009-11-06 | 2018-03-05 | The J David Gladstone Inst | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS |
| MY164376A (en) * | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) * | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
-
2014
- 2014-11-25 BR BR112016010454A patent/BR112016010454A2/pt not_active Application Discontinuation
- 2014-11-25 EA EA201690898A patent/EA038994B1/ru unknown
- 2014-11-25 EP EP14820979.4A patent/EP3074420A2/en not_active Withdrawn
- 2014-11-25 WO PCT/US2014/067360 patent/WO2015081085A2/en not_active Ceased
- 2014-11-25 CA CA2931396A patent/CA2931396C/en active Active
- 2014-11-25 CN CN201480064675.0A patent/CN105899230B/zh not_active Expired - Fee Related
- 2014-11-25 US US15/038,711 patent/US20160289309A1/en not_active Abandoned
- 2014-11-25 MX MX2016006356A patent/MX384909B/es unknown
- 2014-11-25 JP JP2016534640A patent/JP6629201B2/ja not_active Expired - Fee Related
- 2014-11-25 CN CN202010377028.2A patent/CN111569063A/zh active Pending
-
2016
- 2016-05-16 MX MX2021008755A patent/MX2021008755A/es unknown
-
2019
- 2019-04-29 US US16/398,097 patent/US20200102375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504570A5 (2) | ||
| AR104875A1 (es) | Anticuerpos anti-tau y métodos de uso | |
| Dunning et al. | Can Parkinson's disease pathology be propagated from one neuron to another? | |
| WO2014058924A3 (en) | Antibodies recognizing alpha-synuclein | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| NZ748983A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| IL266911B2 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| JP2017502920A5 (2) | ||
| JP2014502141A5 (2) | ||
| JP2018519810A5 (2) | ||
| JP2018505651A5 (2) | ||
| JP2017532288A5 (2) | ||
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| NZ739181A (en) | Anti-pyroglutamated amyloid beta humanized antibodies | |
| AU2017291414B2 (en) | Anti-N3pGLu amyloid beta peptide antibodies and uses thereof | |
| WO2018175752A8 (en) | Optimized antibody compositions for treatment of ocular disorders | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| WO2019098763A3 (ko) | 알파-시누클레인에 대한 항체 및 그 용도 | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| MX2021014274A (es) | Moleculas de union anti-tdp-43 y usos de las mismas. | |
| WO2014204816A3 (en) | Method for assessing protein identity and stability | |
| WO2014160871A8 (en) | Methods and agents for treating alzheimer's disease | |
| Kroksveen et al. | Cerebrospinal fluid proteomics in multiple sclerosis | |
| JP2018535921A5 (2) | ||
| Roca et al. | Chronic neurological disorders and related comorbidities: role of age-associated physiological changes |